Status: current, Defined. Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3690371013 | Rivastigmine in transdermal dosage form | en | Synonym | Inactive | Case insensitive | SNOMED CT core |
| 3690372018 | Product containing rivastigmine in transdermal dosage form (medicinal product form) | en | Fully specified name | Inactive | Case insensitive | SNOMED CT core |
| 3690373011 | Product containing rivastigmine in transdermal dosage form | en | Synonym | Inactive | Case insensitive | SNOMED CT core |
| 3711789012 | Product containing rivastigmine in transdermal dose form (medicinal product form) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
| 3711790015 | Rivastigmine-containing product in transdermal dose form | en | Synonym | Active | Case insensitive | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Rivastigmine-containing product in transdermal dose form | Plays role | Antidementia therapeutic role | true | Inferred relationship | Some | ||
| Rivastigmine-containing product in transdermal dose form | Is a | Antidementia agent | true | Inferred relationship | Some | ||
| Rivastigmine-containing product in transdermal dose form | Has manufactured dose form | Transdermal dose form | true | Inferred relationship | Some | ||
| Rivastigmine-containing product in transdermal dose form | Has active ingredient | Rivastigmine | true | Inferred relationship | Some | 1 | |
| Rivastigmine-containing product in transdermal dose form | Is a | Product manufactured as transdermal dose form | true | Inferred relationship | Some | ||
| Rivastigmine-containing product in transdermal dose form | Is a | Rivastigmine-containing product | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Rivastigmine only product in transdermal dose form | Is a | True | Rivastigmine-containing product in transdermal dose form | Inferred relationship | Some | |
| Rivastigmine 9.5mg/24 hours transdermal patch | Is a | False | Rivastigmine-containing product in transdermal dose form | Inferred relationship | Some | |
| Rivastigmine 4.6mg/24 hours transdermal patch | Is a | False | Rivastigmine-containing product in transdermal dose form | Inferred relationship | Some |
This concept is not in any reference sets
FHIR